產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 22494-42-4 |
|---|---|---|---|
| 分子式 | C13H8F2O | 純度 | >98% |
| 分子量 | 250.2 | 貨號 | abs47027316 |
| 規格 | 25mg | 供貨周期 | 現貨 |
| 主要用途 | used to relieve pain accompanied with in | 應用領域 | 化工,生物產業,農林牧漁,制藥/生物制藥,綜合 |
Diflunisal 22494-42-4
| 產品描述 | |
| 描述 | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis. . |
| 純度 | >98% |
| 儲存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 二氟ni柳;二氟苯水楊酸;MK-647 |
| 外觀 | 白色粉末 |
| 可溶性/溶解性 | DMSO : 50 mg/mL (199.84 mM; Need ultrasonic) Ethanol : 20 mg/mL (79.94 mM) |
| 生物活性 | |
| 靶點 | COX ,p300 |
| In vitro(體外研究) | Diflunisal, an FDA-approved drug containing a salicylic acid substructure, inhibited CBP/p300 more potently than salicylate. Diflunisal exhibits anti-tumor activity against a specific leukemia carrying a t(8;21) translocation, a tumor previously reported to be dependent on p300 in vitro and in vivo. |
| In vivo(體內研究) | Diflunisal-mediated kinetic stabilization of TTR(Rate-limiting transthyretin) should ameliorate TTR amyloidoses, provided that the nonsteroidal anti-inflammatory drug liabilities can be managed clinically. |
| 參考文獻 | |
| 參考文獻 |
|
| 研究領域 | |
| 研究領域 | Immunology CancerTumor biomarkers CancerTumor immunology Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產品咨詢
電話
微信掃一掃